US gold futures traded higher this morning on Wednesday. Investors, meanwhile, focused on some notable insider trades.
When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.3
MSP Recovery
- The Trade: MSP Recovery, Inc. (NASDAQ: MSPR) Director Thomas W Hawkins acquired a total of 50,000 shares at an average price of $1.08. To acquire these shares, it cost $54.15 thousand.
- What’s Happening: MSP Recovery recently reaffirmed its sales guidance.
- What MSP Recovery Does: MSP Recovery Inc is a healthcare recoveries and data analytics company. The business model includes two principal lines of business: Claims Recovery and Chase to Pay Services.
- The Trade: Creatd, Inc. (NASDAQ: CRTD) Executive Chairman Jeremy Frommer acquired a total of 1,247 shares at an average price of $0.84. The insider spent around $1.05 thousand to buy those shares.
- What’s Happening: Creatd recently issued an update on its 2022 slate of three production projects.
- What Creatd Does: Creatd Inc empowers creators, brands, and entrepreneurs through technology and partnership. The company has three platforms, namely Creatd Labs, Creatd Ventures, and Creatd Partners.
Don’t forget to check out our premarket coverage here .
NanoVibronix
- The Trade: NanoVibronix, Inc. (NASDAQ: NAOV) Chief Financial Officer Stephen R. Brown acquired a total of 4,000 shares at an average price of $0.57. To acquire these shares, it cost around $2.3 thousand.
- What’s Happening: NanoVibronix, last month, posted Q1 sales of $272.00K.
- What NanoVibronix Does: NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals.
- The Trade: Better Therapeutics, Inc. (NASDAQ: BTTX) Director Geoffrey Parker acquired a total of 25,000 shares at an average price of $1.45. The insider spent $36.18 thousand to buy those shares.
- What’s Happening: Better Therapeutics recently announced issuance of US patent covering key features of their prescription digital therapeutics platform.
- What Better Therapeutics Does: Better Therapeutics Inc is a prescription digital therapeutics company developing a novel form of cognitive behavioural therapy to address the root causes of cardiometabolic diseases.
Read at Benzinga